Skip to main content

Table 3 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending on stage of clinical disease progression (by FIGO) and in control group

From: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

  Stage of clinical disease progression (by FIGO) Controls
I II III IV n = 80
n = 25 n = 31 n = 60 n = 33
Anti-Hsp60 (AU/ml) 126,99a)b)e) 97,15c)e) 91,92 70,87 62,42
(mean ± SD) ± 121,90 ± 91,82 ± 160,11 ± 78,70 ± 33,92
  % of positive results 46%f) 27%f) 17% 17% 10%
  (> 90 percentile for control group) p = 0.0000 p = 0.0213 p = 0.2047 p = 0.2861
Anti-Hsp65 (AU/ml) 190,34a)b)e) 97,80c)e) 89,36d) 44,17 56,35
(mean ± SD) ± 337,27 ± 90,59 ± 137,58 ± 26,07 ± 35,58
  % of positive results 46%f) 27%f) 21% 0%f) 10%
  (> 90 percentile for control group) p = 0.0000 p = 0.0213 p = 0.0594 p = 0.0493
  1. a)p < 0.05 in group of women with I clinical stage compared to group of women with III clinical stage.
  2. b)p < 0.05 in group of women with I clinical stage compared to group of women with IV clinical stage.
  3. c)p < 0.05 in group of women with II clinical stage compared to group of women with IV clinical stage.
  4. d)p < 0.05 in group of women with III clinical stage compared to group of women with IV clinical stage.
  5. e)p < 0.05 in group of women with I and II clinical stage compared to control group.
  6. f)p < 0.05 in group of women with I, II and IV clinical stage compared to control group.